MITOMICS Study: the Large French Cohort for Mitochondrial Diseases!

Mitochondrial diseases are rare, complex, and often misdiagnosed.

This is why MITOMICS, an ambitious French project funded as part of National Rare Diseases Plan 4, was launched in 2022.

Several teams (CHU Nice, Angers, Imagine Institute, CNRS, Inserm) have joined forces to build a vast clinico-biological database.

The idea: to gather genetic, metabolic, and clinical information from patients to better understand disease mechanisms and pave the way for new targeted therapies.

A decisive step towards precision mitochondrial medicine.

Discover the article here ⬇️

https://www.medecinesciences.org/fr/articles/medsci/full_html/2025/02/msc240260/msc240260.html?fbclid=IwY2xjawN4cjZleHRuA2FlbQIxMABicmlkETBDMDdQWFlrdWNSV3FCUVpjc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqA72X46PcFfQhJQtkoPNgCB9r2kGhHS9Ao5enREuKkmicXaLCLkRXwmD3G0_aem_rm-CTeC64egz6fb7lQ8pGg

Share on:

Subscribe to the AMMi newsletter

We could not confirm your subscription.
Your subscription to our newsletter is confirmed.

More articles in the same category

Researchers from Inserm and the NeuroCentre Magendie (Bordeaux) published a fascinating study in August 2025: they successfully stimulated mitochondrial activity

MEET THE PEOPLE BEHIND Epilepsy Plus – E+ Introducing Emma Del Rey, E+ consultant, Board Member of International Mito Patients,

The FDA (U.S. Food and Drug Administration) has just approved Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d),